Dudediligence.

Cullinan Therapeutics, Inc

CGEMNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$40.6MSep ’24−$47.6MDec ’24−$48.5MMar ’25−$70.1MJun ’25−$50.6MSep ’25−$50.7MDec ’25−$49.7MMar ’26−$53.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$18.9M$0.00none on filenone on filenone on file
Operating income−$68.0M$144.6M−$191.1M−$196.9M−$241.6M
Net income−$65.6M$111.2M−$153.2M−$167.4M−$219.9M
Operating cash flow−$43.4M−$126.7M−$134.3M−$145.3M−$175.8M
Free cash flow−$43.4M−$127.8M−$134.5M−$145.3M−$175.8M
Cash$59.8M$156.2M$98.4M$83.0M$88.3M
Shares outstanding44.3M45.8M42.9M58.5M60.2M